Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Apellis Pharmaceuticals, Inc.

Get SEC filing alerts via email and in your feed for Apellis Pharmaceuticals, Inc.

APLS

Apellis Pharmaceuticals, Inc.

About Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the discovery, development, and commercialization of therapies targeting the complement system to treat diseases with high unmet needs. Its core products include pegcetacoplan-based treatments SYFOVRE for geographic atrophy in age-related macular degeneration and EMPAVELI for paroxysmal nocturnal hemoglobinuria. Apellis serves patients in ophthalmology and rare diseases, leveraging proprietary complement inhibition technology and collaborations for global commercialization.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Apellis Pharmaceuticals, Inc.

1
1
Apellis Pharmaceuticals, Inc. Apellis Pharmaceuticals Reports 61% Revenue Growth and Net Income Turnaround in Latest Quarter

Via official filing (AI summary) | 29 days ago | 0 comments

2
1
Apellis Pharmaceuticals, Inc. Apellis Pharmaceuticals Reports $22.4 Million Net Income for 2025 Driven by SYFOVRE and EMPAVELI Sales

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Apellis Pharmaceuticals, Inc. Apellis Pharmaceuticals Reports 133% Revenue Growth and $215.7 Million Net Income for Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Apellis Pharmaceuticals, Inc. Apellis Pharmaceuticals Reports $178.5M Revenue in Q2 2025, Faces 11% Decline

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Apellis Pharmaceuticals, Inc. Apellis Pharmaceuticals Reports $166.8 Million Revenue in Q1 2025, Net Loss Widens

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Apellis Pharmaceuticals, Inc. Apellis Pharmaceuticals Reports $197.8 Million Net Loss for 2024, Significant Revenue Growth Driven by SYFOVRE

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Apellis Pharmaceuticals, Inc. Apellis Pharmaceuticals Reports 78% Revenue Growth, Improved Financials in Latest Quarter

Via official filing (AI summary) | over 1 year ago | 0 comments